Colorectal cancer is a worldwide leading cause of death accounting for high-rate mortality. Mutations in the epidermal growth factor receptor and RAS/MAPK pathways, as well as altered methylation genes profiles, have been described as molecular mechanisms promoting and sustaining tumour development and progression. Aberrant methylation is a well-known epigenetic mechanism involved in gene regulation; particularly several genes were reported as hypermethylated in CRC. Recently, it was shown that epigenetic alterations in genes such as neuropeptide y, proenkephalin and Wnt inhibitory factor 1 can be used as promising disease biomarkers. Almost all methods developed for the DNA methylation analysis combined next generation sequencing, conventional qRT-PCR or ddPCR with the prior DNA modification with sodium bisulfite.
Methods and results:
We implemented a ddPCR method to assess the methylation status of Wnt inhibitory factor 1 and neuropeptide y using the methylation sensitive restriction enzyme approach that does not impact on DNA quality and guarantees the discrimination of DNA methylation independent of bisulfite conversion.
Conclusions:
We showed that this method is robust and sensitive also allowing the monitoring of CRC disease progression when applied to circulating free DNA samples from liquid biopsies, proving to be a fast and easy to implement assay to be used for the monitoring of the methylation pattern of clinically relevant target genes.
BrayFFerlayJSoerjomataramI, et al394 CA: A Cancer Journal for Clinicians Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin2018; 68: 394–424.
2.
WangJYHsiehJSChangMY, et alMolecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg2004; 28: 721–726.
3.
SchwarzenbachHStoehlmacherJPantelK, et alDetection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann N Y Acad Sci2008; 1137: 190–196.
4.
BettegowdaCSausenMLearyRJ, et alDetection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med2014; 6: 224ra24.
5.
MohanSHeitzerEUlzP, et alChanges in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet2014; 10: e1004271.
6.
GarlanFLaurent-PuigPSefriouiD, et alEarly evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study). Clin Cancer Res2017; 23: 5416–5425.
7.
MoatiETalyVDidelotA, et alRole of circulating tumor DNA in the management of patients with colorectal cancer. Clin Res Hepatol Gastroenterol2018; 42: 396-4002.
8.
TaiebJTalyVVernereyD, et alAnalysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration. Ann Oncol2019; 30: v867.
9.
CremoliniCRossiniDDell’AquilaE, et alRechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol2019; 5: 343–350.
10.
GerratanaLBasileDFranzoniA, et alPlasma-based longitudinal evaluation of ESR1 epigenetic status in hormone receptor-positive HER2-negative metastatic breast cancer. Front Oncol2020; 10: 550185.
11.
GerratanaLDavisAAPolanoM, et alUnderstanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools. Eur J Cancer2021; 143: 147–57.
12.
BasileDGalloisCPuglisiF, et alPractices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey. Clin Res Hepatol Gastroenterol2021; 45: 1–13 .
13.
JungGHernández-IllánEMoreiraL, et alEpigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol2020; 17: 111–130.
14.
RoperchJPIncittiRForbinS, et alAberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer. BMC Cancer2013; 13: 1–10.
15.
GarrigouSPerkinsGGarlanF, et alA study of hypermethylated circulating tumor DNA as a universal colorectal cancer biomarker. Clin Chem2016; 62: 1129–1139.
16.
PandeyRVPulvererWKallmeyerR, et alMSP-HTPrimer: a high-throughput primer design tool to improve assay design for DNA methylation analysis in epigenetics. Clin Epigenetics2016; 8: 1–10.
17.
PulvererWKruusmaaKSchönthalerS, et alMultiplexed dna methylation analysis in colorectal cancer using liquid biopsy and its diagnostic and predictive value. Curr Issues Mol Biol2021; 43: 1419–1435.
18.
QuanPLSauzadeMBrouzesE.dPCR: A technology review. Sensors (Basel)2018; 18: 1271.
19.
Laurent-PuigPPekinDNormandC, et alClinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res2015; 21: 1087–1097.
EhrichMZollSSurS, et alA new method for accurate assessment of DNA quality after bisulfite treatment. Nucleic Acids Res2007; 35: e29.
22.
LeontiouCAHadjidanielMDMinaP, et alBisulfite conversion of DNA: Performance comparison of different kits and methylation quantitation of epigenetic biomarkers that have the potential to be used in non-invasive prenatal testing. PLoS One2015; 10: e0135058–e0135058.
23.
YiSLongFChengJ, et alAn optimized rapid bisulfite conversion method with high recovery of cell-free DNA. BMC Mol Biol2017; 18: 1–8.
24.
NellRJvan SteenderenDMengerNV, et alQuantification of DNA methylation independent of sodium bisulfite conversion using methylation-sensitive restriction enzymes and digital PCR. Hum Mutat2020; 41: 2205.
25.
HashimotoKKokubunSItoiE, et alImproved quantification of DNA methylation using methylation-sensitive restriction enzymes and real-time PCR. Epigenetics2007; 2: 86–91.
26.
RoachHIYamadaNCheungKSC, et alAssociation between the abnormal expression of matrix-degrading enzymes by human osteoarthritic chondrocytes and demethylation of specific CpG sites in the promoter regions. Arthritis Rheum2005; 52: 3110–3124.
27.
LockerGYHamiltonSHarrisJ, et alASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol2006; 24: 5313–5327.
28.
MlecnikBBindeaGPagèsF, et alTumor immunosurveillance in human cancers. Cancer Metastasis Rev2011; 30: 5–12.
29.
GuZEilsRSchlesnerM.Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics2016; 32: 2847–2849.
30.
GradyWMMarkowitzSD.The molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screening. Dig Dis Sci2015; 60: 762–772.
31.
OversAFlammangMHervouetE, et alThe detection of specific hypermethylated WIF1 and NPY genes in circulating DNA by crystal digital PCRTM is a powerful new tool for colorectal cancer diagnosis and screening. BMC Cancer2021; 21: 1–12
32.
LockeWJGuanzonDMaC, et al. DNA methylation cancer biomarkers: Translation to the clinic. Front Genet 2019; 10:1150. doi: 10.3389/fgene.2019.01150.
33.
KanedaATakaiDKaminishiM, et alMethylation-sensitive representational difference analysis and its application to cancer research. Ann N Y Acad Sci2003; 983: 131–41.
34.
HagiharaAMiyamotoKFurutaJ, et alIdentification of 27 5 0 CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. Oncogene2004; 23: 8705–8710.
35.
HuaDHuYWuYY, et alQuantitative methylation analysis of multiple genes using methylation-sensitive restriction enzyme-based quantitative PCR for the detection of hepatocellular carcinoma. Exp Mol Pathol2011; 91: 455–460.
36.
CebratMStrzadalaLKisielowP.Wnt inhibitory factor-1: A candidate for a new player in tumorigenesis of intestinal epithelial cells. Cancer Lett2004; 206: 107–113.
37.
TaniguchiHYamamotoHHirataT, et alFrequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene2005; 24: 7946–7952.
38.
WissmanCWildPJKaiserS, et alWIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol2003; 201: 204–212.
39.
MazieresJHeBYouL, et alWnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res2004; 64: 4717–4720.
40.
VeeckJWildPJFuchsT, et alPrognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. BMC Cancer2009; 9: 217.
41.
LambivWLVassalloIDelorenziM, et alThe Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro Oncol2011; 13: 736–747.
42.
AiLTaoQZhongS, et alInactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis2006; 27: 1341–1348.
43.
MortonGJSchwartzMW.The NPY=AgRP neuron and energy homeostasis. Int J Obesity2001; 25: Suppl 5:S56-62.
44.
HalldénGHadiMHongHT, et alY receptor-mediated induction of CD63 transcripts, a tetraspanin determined to be necessary for differentiation of the intestinal epithelial cell line, hBRIE 380i cells. J Biol Chem1999; 274: 27914–27924.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
